Cecilia Carpio

Cecilia Carpio

Auto-generated profile, based on publicly available information

Cecilia Carpio

Department of Hematology, University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) BARCELONA, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in The Lancet Haematology
Verified
Journal Article
Closed access
AYAnas Younes
Anas Younes
JBJoshua Brody
Joshua Brody
CCCecilia Carpio
Cecilia Carpio
ALArmando Lopez-Guillermo
Armando Lopez-Guillermo
DBDina Ben-Yehuda
Dina Ben-Yehuda
WJWojciech Jurczak
Wojciech Jurczak

2 December 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ESEytan M. Stein
Eytan M. Stein
DDDaniel J. DeAngelo
Daniel J. DeAngelo
JCJörg Chromik
Jörg Chromik
MCManik Chatterjee
Manik Chatterjee
SBSebastian Bauer
Sebastian Bauer
CCCecilia Carpio
Cecilia Carpio
Purpose: This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Experimental Design: Initial dosing regimens were: 1A (Day 1; 21-day cycle; dose 12.5-350 mg); 2A (Days 1-14; 28-day cycle; dose 1-20 mg). Alternative regimens included 1B (Days 1 and 8; 28-day cycle) and 2C (Days 1-7; 28-day cycle). The primary endpoint was incidence of dose-limiting toxicities (DLTs) during Cycle 1. Results: Overall, 115 patients with solid tumors and 93 with hematologic malignancies received treatment. DLTs occurred in 8/92 patients with solid tumors and 10/53 patients with hematologic malignancies. In solid tumors, an RDE of 120 mg was defined in 1B. In hematologic tumors, RDEs were defined in 1A: 250 mg, 1B: 120 mg, and 2C: 45 mg. More patients with hematologic malignancies compared with solid tumors experienced Grade 3/4 treatment-related adverse events (71% vs. 45%), most commonly resulting from myelosuppression. These were more frequent and severe in patients with hematologic malignancies; 22 patients exhibited tumor lysis syndrome. Overall response rates at the RDEs were 10.3% (95% CI, 2.2-27.4) in solid tumors and 4.2% (95% CI, 0.1-21.1), 20% (95% CI, 4.3-48.1), or 22.2% (95% CI, 8.6-42.3) in acute myeloid leukemia (AML) in 1B, 1A, and 2C, respectively. Conclusions: A common safety profile was identified and preliminary activity was noted, particularly in AML. Comprehensive investigation of dosing regimens yielded recommended doses/regimens for future combination studies.

26 March 2020 in Blood
Verified
Journal Article
Open access
PDF file
CCCecilia Carpio
Cecilia Carpio
RBReda Bouabdallah
Reda Bouabdallah
LYLoïc Ysebaert
Loïc Ysebaert
JSJuan-Manuel Sancho
Juan-Manuel Sancho
GSGilles Salles
Gilles Salles
VRVincent Ribrag
Vincent Ribrag
Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are limited, with no standard of care; prognosis is poor, with 4- to 6-month median survival. Avadomide (CC-122) is a cereblon-modulating agent with immunomodulatory and direct antitumor activities. This phase 1 dose-expansion study assessed safety and clinical activity of avadomide monotherapy in patients with de novo R/R DLBCL and transformed lymphoma. Additionally, a novel gene expression classifier, which identifies tumors with a high immune cell infiltration, was shown to enrich for response to avadomide in R/R DLBCL. Ninety-seven patients with R/R DLBCL, including 12 patients with transformed lymphoma, received 3 to 5 mg avadomide administered on continuous or intermittent schedules until unacceptable toxicity, disease progression, or withdrawal. Eighty-two patients (85%) experienced ≥1 grade 3/4 treatment-emergent adverse events (AEs), most commonly neutropenia (51%), infections (24%), anemia (12%), and febrile neutropenia (10%). Discontinuations because of AEs occurred in 10% of patients. Introduction of an intermittent 5/7-day schedule improved tolerability and reduced frequency and severity of neutropenia, febrile neutropenia, and infections. Among 84 patients with de novo R/R DLBCL, overall response rate (ORR) was 29%, including 11% complete response (CR). Responses were cell-of-origin independent. Classifier-positive DLBCL patients (de novo) had an ORR of 44%, median progression-free survival (mPFS) of 6 months, and 16% CR vs an ORR of 19%, mPFS of 1.5 months, and 5% CR in classifier-negative patients (P = .0096). Avadomide is being evaluated in combination with other antilymphoma agents. This trial was registered at www.clinicaltrials.gov as #NCT01421524.

20 October 2011 in Blood
Verified
Journal Article
Closed access
PDF file
ECEva Calpe
Eva Calpe
CCCarles Codony
Carles Codony
MBMaria Joao Baptista
Maria Joao Baptista
PAPau Abrisqueta
Pau Abrisqueta
CCCecilia Carpio
Cecilia Carpio
MCMarta Crespo
Marta Crespo
ZAP-70 in chronic lymphocytic leukemia (CLL) has been associated with enhanced B-cell receptor (BCR) signaling, survival, and migration. We investigated whether ZAP-70 can directly govern migration and the underlying mechanisms. In the ZAP-70 stably transfected Ramos cell line, IgM stimulation, but no IgD, enhanced phosphorylation of ERK1/2, Akt and Syk, and delayed IgM and CD79b internalization. In contrast, in the Raji cell line, where ZAP-70 was constitutively phosphorylated, ERK1/2, but not Akt, was phosphorylated, suggesting that MAPK pathway mediates ZAP-70 effects. BCR stimulation modulated the expression of CCR7, CXCR4, CXCR5, CD44, CD49d, and CD62L, which were up-regulated in ZAP-70–positive CLL primary subclones. The most dramatic change after BCR engagement in ZAP-70-transfected cells was CCR7 up-regulation, this being impaired by ERK1/2 inhibition and translating into both increased signaling and migration toward CCL21. Primary CLL subclones with high ZAP-70 expression showed increased migration toward CCL21. In conclusion, ZAP-70 ectopic expression led to enhanced BCR signaling after IgM stimulation and increased the expression of CCR7 predominantly via ERK1/2, increasing the response and migration toward CCL21. In primary CLL samples, cellular subsets with high ZAP-70 expression had increased expression of adhesion molecules and chemokine receptors in addition to an enhanced ability to migrate toward CCL21.

3 December 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
NPNoelia Purroy
Noelia Purroy
PAPau Abrisqueta
Pau Abrisqueta
JCJúlia Carabia
Júlia Carabia
CCCecilia Carpio
Cecilia Carpio
CPCarles Palacio
Carles Palacio
MCMarta Crespo
Marta Crespo
Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo

19 September 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
EMEster Marquez-Algaba
Ester Marquez-Algaba
GIGloria Iacoboni
Gloria Iacoboni
BPBerta Pernas
Berta Pernas
JEJuliana Esperalba
Juliana Esperalba
ILIbai Los-Arcos
Ibai Los-Arcos
IRIsabel Ruíz-Camps
Isabel Ruíz-Camps
Data are scarce on cytomegalovirus (CMV) replication in patients receiving CD19-directed chimeric antigen receptor (CAR) T cell treatment. Here we describe the incidence, severity, and management of CMV infection in patients with aggressive B cell lymphoma treated with CAR T cell therapy. In this retrospective observational study, we analyzed CMV viral load and its clinical impact in patients with aggressive B cell lymphoma receiving CAR T cell therapy between July 2018 and December 2021 at a single center. Patients with a negative baseline CMV IgG or a previous allogeneic stem cell transplantation were excluded. CMV replication was determined in whole blood. Overall, 105 patients met the study's inclusion criteria. Ten patients presented with CMV replication before CAR T cell infusion and were analyzed separately. Forty-two of the remaining 95 patients (44%) had at least 1 positive CMV determination, with a viral load ≥1000 IU/mL in 21 patients (22%). Four patients in the main cohort (N = 95) and 4 patients in the preinfusion replication group (N = 10) achieved a viral load >10,000 IU/mL. Only 7 patients received preemptive antiviral treatment. No CMV end-organ disease was reported. The sole independent risk factor associated with CMV viremia ≥1000 IU/mL was dexamethasone treatment (odds ratio, 8.4; 95% confidence interval, 2.4 to 36.6; P = .002). Based on our findings, we designed an algorithm for CMV management in this setting. CMV replication is relatively frequent in patients with aggressive B cell lymphoma receiving CAR T cell therapy. It is usually self-limited and not associated with end-organ disease. Patients receiving dexamethasone or harboring CMV replication before infusion might benefit from active surveillance and preemptive treatment strategies.